SormaniMPBruzziP.MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials. Lancet Neurol2013; 12(7): 669–676.
3.
SteinmanL.Immunology of relapse and remission in multiple sclerosis. Annu Rev Immunol2014; 32: 257–281.
4.
Di GregorioMGaetaniLEusebiP, et al. Treatment of multiple sclerosis relapses with high-dose methylprednisolone reduces the evolution of contrast-enhancing lesions into persistent black holes. J Neurol2018; 265(3): 522–529.
5.
SchockeMFBergerTFelberSR, et al. Serial contrast-enhanced magnetic resonance imaging and spectroscopic imaging of acute multiple sclerosis lesions under high-dose methylprednisolone therapy. NeuroImage2003; 20(2): 1253–1263.
6.
BagnatoFJeffriesNRichertND, et al. Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. Brain2003; 126(Pt 8): 1782–1789.
7.
SlokaJSStefanelliM.The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Mult Scler2005; 11(4): 425–432.
8.
GasperiniCPozzilliCBastianelloS, et al. Effect of steroids on Gd-enhancing lesions before and during recombinant beta interferon 1a treatment in relapsing remitting multiple sclerosis. Neurology1998; 50(2): 403–406.
9.
Then BerghFKumpfelTSchumannE, et al. Monthly intravenous methylprednisolone in relapsing—remitting multiple sclerosis—reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations. BMC Neurol2006; 6: 19.
10.
ZivadinovRZorzonMDe MasiR, et al. Effect of intravenous methylprednisolone on the number, size and confluence of plaques in relapsing-remitting multiple sclerosis. J Neurol Sci2008; 267(1–2): 28–35.
